New GLP-1 Pill Matches Injectable Weight-Loss Drugs in Landmark Trial

Boston — A new oral GLP-1 receptor agonist delivered weight loss comparable to leading injectable therapies in a large phase 3 trial published this week in the New England Journal of Medicine. Participants taking the daily pill lost an average of 21.4 percent of body weight over 78 weeks, versus 22.1 percent for semaglutide and 24.3 percent for tirzepatide in prior head-to-head data.

The trial, involving 3,412 adults with obesity or overweight and at least one cardiovascular risk factor, was conducted across 214 sites in North America, Europe, and Asia. Discontinuation rates were slightly lower than for injectables, and gastrointestinal side effects were milder in the first eight weeks.

Experts say an effective oral option could dramatically expand access. 'Injections have been a barrier for many patients, especially in primary care, in older adults, and in lower-resource settings,' said Dr. Fatima Cody Stanford of Harvard Medical School, who was not involved in the trial. Pill formats are also easier to distribute globally without cold-chain infrastructure.

The manufacturer expects regulatory submissions in the U.S., European Union, and Japan by the end of the year, with potential launch in the second half of 2027. Analysts at Morgan Stanley project the global GLP-1 market could exceed 250 billion dollars by 2032, driven partly by pill-based options.

Insurance coverage remains a challenge. Only 38 percent of employer-sponsored U.S. plans currently cover GLP-1s for obesity, though momentum is building after Medicare's 2025 policy change. In the U.K., NICE is expected to review the oral therapy under an accelerated pathway.

Cardiovascular outcome data from a separate 22,000-patient trial is due in early 2027 and will help determine whether pill-based GLP-1s can match the heart and kidney benefits already documented for injectables.